Insilico Medicine

Feng got his bachelor’s degree in USTC (University of Science and Technology of China) in 1998. After 2 years of graduate research (M.Sc) in National University of Singapore, he went to Harvard University to pursue his Ph.D degree in the Department of Chemistry and Chemical Biology. He completed the syntheses of two natural products including Terpestacin (an anti-HIV agent) and Kedarcidin Chromophore (an anti-tumor antibiotics). After got his Ph.D, he joined the pharmaceutical company GlaxoSmithKline in CVU CEDD (Cardiovascular & Urogenital Center of Excellence in Drug Discovery) in Philadelphia in 2007 where he involved in the discovery of small molecule drugs for cardiovascular diseases. One year later, in 2008, he transferred to the GSK R&D center in Shanghai. He, as the lab manager, helped the chemistry head to set up and maintain a fully functional chemistry lab. He eventually took team leader/chemistry leader/program leader roles in the discovery of small molecule drugs for neurodegenerative diseases and neuroinflammation diseases. He managed a group of 5 internal chemists and 3 groups of 12+ chemists in CROs plus two CRO integrated service team (6 chemists each team). He had successfully delivered a Phase II compound, a small molecule candidate towards FTIH (in Preclinical Development), a small molecule in commit-to-preclinical development stage, and several chemical series with in vivo efficacy for lead optimization. He is currently the program leader to lead the matrix team consisting of chemistry, biology, DMPK, safety, CMC, Fragment-Based Drug Discovery (FBDD), and Encoded Library Technology (ELT) teams for the discovery of small molecules for the treatment of neuroinflammation diseases. He has been promoted twice (from senior scientist to principle scientist in 2009 and to associate director in 2012) during the 8 years of research career in GlaxoSmithKline.

Financial Translator MA in Translation in CUHK

Through my professional experience, I have gained a deep understanding of the core of marketing and have developed my own business philosophy. I believe that what really matters in the market is the customer and their needs, not the product itself, and that we must put the customer's needs first. On the road ahead, I will continue to deepen my knowledge base and strive to provide better services to our customers.

I am a physician executive and biopharmaceutical leader with over 20 years of experience…

Luoheng is a Vice President of Chemistry of InSilico Medicine. He is currently working on small molecule discovery projects and AI drug discovery, leading multiple internal Medicinal Chemistry PLs and external chemists, as well as the cyclic peptide platform of InSilico Medicine. Prior to the current position, he had been a supervisor/project leader/core team member in 20+ endocrine/oncology/immunology/CNS projects in T2L/LO/LLO/IND enabling stages, with 3 of them successfully advanced to Phase 1 clinical trials (USP1 inhibitor XL309/ISM3091 in US, QPCTL inhibitor ISM8207/FH2201 in China, and KAT6 inhibitor MEN2312/ISM5043 in US), 1 achieved FDA IND clearance (ENPP1 inhibitor ISM5939) and 5 other projects successfully delivered clinical candidates. In Q3 2023, the USP1 inhibitor XL309/ISM3091 was licensed out to Exelixis, with an upfront payment to InSilico of $80 million. In Q1 2024, the KAT6 inhibitor MEN2312/ISM5043 was licensed out to Menarini. Luoheng has been awarded the title of "Mingzhu Elite Talent" under the "Mingzhu Program" in Shanghai Pudong New Area for the year 2023 Luoheng was a volunteer for American Chemical Society Shanghai Chapter. He served as the secretary of the chapter in 2015 - 2017.